Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer

The clinical success of adoptive immunotherapy of cancer relies on the selection of target antigens that are highly expressed in tumor cells but absent in essential normal tissues. A group of genes that encode the cancer/testis or cancer germline antigens have been proposed as ideal targets for immunotherapy due to their high expression in multiple cancer types and their restricted expression in immunoprivileged normal tissues. In the present work we report the isolation and characterization of human T cell receptors (TCRs) with specificity for synovial sarcoma X breakpoint 2 (SSX2), a cancer/testis antigen expressed in melanoma, prostate cancer, lymphoma, multiple myeloma and pancreatic cancer, among other tumors. We isolated seven HLA-A2 restricted T cell receptors from natural T cell clones derived from tumor-infiltrated lymph nodes of two SSX2-seropositive melanoma patients, and selected four TCRs for cloning into retroviral vectors. Peripheral blood lymphocytes (PBL) transduced with three of four SSX2 TCRs showed SSX241-49 (KASEKIFYV) peptide specific reactivity, tumor cell recognition and tetramer binding. One of these, TCR-5, exhibited tetramer binding in both CD4 and CD8 cells and was selected for further studies. Antigen-specific and HLA-A*0201-restricted interferon-γ release, cell lysis and lymphocyte proliferation was observed following culture of TCR engineered human PBL with relevant tumor cell lines. Codon optimization was found to increase TCR-5 expression in transduced T cells, and this construct has been selected for development of clinical grade viral vector producing cells. The tumor-specific pattern of expression of SSX2, along with the potent and selective activity of TCR-5, makes this TCR an attractive candidate for potential TCR gene therapy to treat multiple cancer histologies.

[1]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[2]  M. Fu,et al.  Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? , 2013, Seminars in oncology.

[3]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[4]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[5]  Benjamin Djulbegovic,et al.  Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials , 2013, Journal of Hematology & Oncology.

[6]  C. Shaffer,et al.  Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2 , 2012, BMC Genomics.

[7]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[8]  Steven A. Rosenberg,et al.  Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.

[9]  P. Rutkowski,et al.  Downstream and Intermediate Interactions of Synovial Sarcoma-Associated Fusion Oncoproteins and Their Implication for Targeted Therapy , 2012, Sarcoma.

[10]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[11]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[12]  Jun Luo,et al.  Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy , 2011, Journal of Translational Medicine.

[13]  J. Lang,et al.  Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. , 2011, Cancer research.

[14]  H. Shiku,et al.  Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. , 2011, Blood.

[15]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[16]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Wargo,et al.  A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer , 2011, The Journal of Immunology.

[19]  S. Rosenberg,et al.  Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials , 2010, Clinical Cancer Research.

[20]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[21]  C. Bokemeyer,et al.  Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma , 2009, Clinical Cancer Research.

[22]  S. Rosenberg,et al.  Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells , 2009, Clinical Cancer Research.

[23]  J. Wargo,et al.  Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression , 2009, Cancer Immunology, Immunotherapy.

[24]  Oliver Hofmann,et al.  Genome-wide analysis of cancer/testis gene expression , 2008, Proceedings of the National Academy of Sciences.

[25]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Rosenberg,et al.  Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition , 2008, Gene Therapy.

[27]  Morten Nielsen,et al.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..

[28]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[29]  D. McNeel,et al.  Inducible expression of a prostate cancer‐testis antigen, SSX‐2, following treatment with a DNA methylation inhibitor , 2007, The Prostate.

[30]  C. Bokemeyer,et al.  Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. , 2007, Blood.

[31]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[32]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[33]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[34]  A. Suri.  Cancer testis antigens – their importance in immunotherapy and in the early detection of cancer , 2006, Expert opinion on biological therapy.

[35]  K. Irvine,et al.  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. , 2006, Cancer research.

[36]  J. Keats,et al.  SSX Cancer Testis Antigens are Expressed in Most Multiple Myeloma Patients: Co-Expression of SSX1, 2, 4, and 5 Correlates With Adverse Prognosis and High Frequencies of SSX-Positive PCs , 2005, Journal of immunotherapy.

[37]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[38]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[39]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[40]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[41]  D. Speiser,et al.  Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma1 , 2005, The Journal of Immunology.

[42]  D. Speiser,et al.  Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. , 2003, Cancer research.

[43]  Yao-Tseng Chen,et al.  The SSX gene family: Characterization of 9 complete genes , 2002, International journal of cancer.

[44]  Danila Valmori,et al.  Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1 , 2002, The Journal of Immunology.

[45]  A. V. van Kessel,et al.  Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. , 2000, Cancer research.

[46]  R. Morgan,et al.  A simple and reliable method for screening retroviral producer clones without selectable markers. , 1997, Human gene therapy.

[47]  H. Rammensee,et al.  The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. , 1996, Cancer research.

[48]  B. Gusterson,et al.  Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel‐associated box in human synovial sarcoma. , 1995, The EMBO journal.

[49]  C. Cooper,et al.  Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma , 1994, Nature Genetics.